Abdel SC, Maher CG, Furmage AM, et al. Strengthening the reporting of harms of all interventions in clinical trials. Med J Aust. 2022;217(10):502–4.
Polasek TM, Schuck V. Improving the efficiency of clinical pharmacology studies. Clin Pharmacol Drug Dev. 2023;12:771–4.
Doogue MP, Polasek TM. The ABCD of clinical pharmacokinetics. Ther Adv Drug Saf. 2013;4:5–7.
Pollin W, Perlin S. Psychiatric evaluation of “normal control” volunteers. Am J Psychiatry. 1958;115:129–33.
Rosenthal R, Rosnow RL. The volunteer subject. Hum Relat. 1965;18:389–406.
Walsh JA, Nash MM. Personality characteristics of volunteers for medical research. Crim Justic Behav. 1978;5:99–116.
Cowles M, Davis C. The subject matter of psychology: Volunteers. Br J Soc Psychol. 1987;26:97–102.
Cami J, Llorente M, Farre M, et al. Personality of healthy volunteers participating in phase I clinical trials. Pers Individ Differ. 1989;11:1199–200.
Ball CJ, McLaren PM, Morrison PJ. The personality structure of ‘normal’ volunteers. Br J Clin Pharmacol. 1993;4:369–71.
Berto D, Milleri S, Squassante L, et al. Evaluation of personality as a component of the healthy condition of volunteers participating in phase I studies. Eur J Clin Pharmacol. 1996;5:209–13.
Tishler C, Apseloff G, Bartholomae S, et al. Are normal healthy research volunteers psychologically healthy? A pilot investigation. Exp Clin Psychopharmacol. 2007;6:539–45.
Wei Y, Li H, Wang H, Zhang S, et al. Psychological status of volunteers in a phase I clinical trial assessed by symptom checklist 90 (SCL-90) and Eysenck Personality Questionnaire (EPQ). Med Sci Monit. 2018;24:4968–73.
Farre M, Lamas X, Cami J. Sensation seeking amongst healthy volunteers participating in phase I clinical trials. Br J Clin Pharmacol. 1995;39:405–9.
Gustavsson JP, Asberg M. The healthy control subject in psychiatric research: impulsiveness and volunteer bias. Acta Psychiatr Scand. 2007;96:325–8.
Pieters MS, Jennekens-Schinkel A, Shoemaker HC. Self-selection for personality variables among healthy volunteers. Br J Clin Pharmacol. 1992;33:101–6.
Royal Australian and New Zealand College of psychiatrists. Clinical Memorandum Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression. 2023. https://www.ranzcp.org/getmedia/0cf57ea2-0bd7-4883-9155-d2ba1958df86/cm-therapeutic-use-of-mdma-for-ptsd-and-psilocybin-for-treatment-resistant-depression.pdf. Accessed Dec 2023.
Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016;35(12):1334–55.
Kööts-Ausmees L, Schmidt M, Esko T, et al. The role of the five factor personality traits in self-reported general health. Eur J Personal. 2016;30(5):492–504.
Watson D. Strangers’ ratings of five robust personality factors: Evidence of a surprising convergence with self-report. J Person Soc Psychology. 1989;57(1):120–8.
Costa PT, McCrae RR. Neuroticism, somatic complaints, and disease: is the bark worse than the bite? J Pers. 1987;55(2):299–316.
Jerram KL, Coleman PG. The big five personality traits and reporting of health problems and health behaviour in old age. Br J Health Psychol. 1999;1999(4):181–92.
Realo A, Van Middendorp H, Koots-Ausmees L, et al. Role of personality traits in reporting the development of adverse drug reactions: a prospective cohort study of the Estonian general population. BMJ Open. 2018;8:e022428.
Almeida L, Falcão A, Vaz-da-Silva M, et al. Personality characteristics of volunteers in Phase 1 studies and likelihood of reporting adverse events. Int J Clin Pharmacol Ther. 2008;46:340–8.
Almeida L, Kasdan TB, Nunes T, et al. Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events. Eur J Clin Pharmacol. 2008;64:575–82.
Foster JM, Sanderman R, van der Molen T. Personality influences the reporting of side effects of inhaled corticosteroids in asthma patients. J Asthma. 2008;45:664–9.
Davis C, Ralevski E, Kennedy S, et al. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. J Clin Psychopharmacol. 1995;15:347–52.
Amare AT, Schubert KO, Tekola-Ayele F, et al. Association of polygenic score for personality traits and response to selective serotonin re-uptake inhibitors in patients with major depressive disorder. Front Psychiatry. 2018;9:65.
Xu F. Effect of personality type on pharmacodynamics through changing pharmacokinetics. Med Hypotheses. 2007;69:1131–4.
Tishler C, Bartholomae S, Rhodes A. Personality profiles of normal healthy research volunteers: a potential concern for clinical drug trial investigators? Med Hypotheses. 2005;65:1–7.
Thomas A. The Alternative Model of Personality Disorders (AMPD) from the Perspective of the Five-Factor Model. Psychopathology. 2020;53:149–56.
Rucker J, Jafari H, Mantingh T, et al. Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. BMJ Open. 2021;11(12):e056091.
Add Comment